Pier Capital LLC Has $3.50 Million Position in Olema Pharmaceuticals, Inc. $OLMA

Pier Capital LLC reduced its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 73.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 140,101 shares of the company’s stock after selling 384,148 shares during the quarter. Pier Capital LLC’s holdings in Olema Pharmaceuticals were worth $3,503,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Torren Management LLC acquired a new stake in Olema Pharmaceuticals during the fourth quarter worth about $44,000. Russell Investments Group Ltd. acquired a new stake in Olema Pharmaceuticals during the third quarter worth about $53,000. American Century Companies Inc. acquired a new stake in Olema Pharmaceuticals during the second quarter worth about $54,000. Creative Planning acquired a new stake in Olema Pharmaceuticals during the second quarter worth about $83,000. Finally, Nisa Investment Advisors LLC grew its position in Olema Pharmaceuticals by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after buying an additional 477 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total value of $606,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 16.36% of the company’s stock.

Olema Pharmaceuticals Stock Performance

OLMA stock opened at $15.13 on Friday. The company has a 50 day moving average price of $16.58 and a 200 day moving average price of $20.27. Olema Pharmaceuticals, Inc. has a fifty-two week low of $3.89 and a fifty-two week high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.95 and a quick ratio of 9.95. The stock has a market capitalization of $1.32 billion, a PE ratio of -8.13 and a beta of 2.05.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01. Analysts forecast that Olema Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Wall Street Analyst Weigh In

OLMA has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Jefferies Financial Group started coverage on Olema Pharmaceuticals in a report on Thursday, March 19th. They set a “buy” rating and a $40.00 price objective on the stock. Stifel Nicolaus started coverage on Olema Pharmaceuticals in a report on Wednesday, February 11th. They set a “buy” rating and a $48.00 price objective on the stock. Oppenheimer reaffirmed an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Finally, Guggenheim lowered their price target on Olema Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $44.40.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.